Antigenics Announces Expansion of Phase II Trial in Glioma

Antigenics, Inc. Monday announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage vaccine; vitespen), Antigenics’ personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.
TheStreet